BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu H, Gao Y, Shi HL, Qin LY, Huang F, Lan YY, Zhang BB, Hu ZB, Wu XJ. Astragaloside IV improves lipid metabolism in obese mice by alleviation of leptin resistance and regulation of thermogenic network. Sci Rep 2016;6:30190. [PMID: 27444146 DOI: 10.1038/srep30190] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Leung Kwan KK, Wong TY, Wu QY, Xia Dong TT, Lam H, Keung Tsim KW. Mass spectrometry-based multi-omics analysis reveals the thermogenetic regulation of herbal medicine in rat model of yeast-induced fever. J Ethnopharmacol 2021;279:114382. [PMID: 34197959 DOI: 10.1016/j.jep.2021.114382] [Reference Citation Analysis]
2 Graziani V, Scognamiglio M, Esposito A, Fiorentino A, D’abrosca B. Chemical diversity and biological activities of the saponins isolated from Astragalus genus: focus on Astragaloside IV. Phytochem Rev 2019;18:1133-66. [DOI: 10.1007/s11101-019-09626-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
3 Zhou B, Zhou DL, Wei XH, Zhong RY, Xu J, Sun L. Astragaloside IV attenuates free fatty acid-induced ER stress and lipid accumulation in hepatocytes via AMPK activation. Acta Pharmacol Sin 2017;38:998-1008. [PMID: 28344322 DOI: 10.1038/aps.2016.175] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
4 Zhou H, Ma C, Wang C, Gong L, Zhang Y, Li Y. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease. Eur J Pharmacol 2021;898:173976. [PMID: 33639194 DOI: 10.1016/j.ejphar.2021.173976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Dai X, Feng J, Chen Y, Huang S, Shi X, Liu X, Sun Y. Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Chin Med 2021;16:68. [PMID: 34344394 DOI: 10.1186/s13020-021-00469-4] [Reference Citation Analysis]
6 Zhang W, Liu M, Yang L, Huang F, Lan Y, Li H, Wu H, Zhang B, Shi H, Wu X. P-glycoprotein Inhibitor Tariquidar Potentiates Efficacy of Astragaloside IV in Experimental Autoimmune Encephalomyelitis Mice. Molecules 2019;24:E561. [PMID: 30717494 DOI: 10.3390/molecules24030561] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
7 Wang C, Li Y, Hao M, Li W. Astragaloside IV Inhibits Triglyceride Accumulation in Insulin-Resistant HepG2 Cells via AMPK-Induced SREBP-1c Phosphorylation. Front Pharmacol 2018;9:345. [PMID: 29713279 DOI: 10.3389/fphar.2018.00345] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
8 Gu M, Zhang S, Zhao Y, Huang J, Wang Y, Li Y, Fan S, Yang L, Ji G, Tong Q, Huang C. Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling. Pharmacol Res 2017;121:22-32. [PMID: 28428116 DOI: 10.1016/j.phrs.2017.04.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
9 Wang X, Yang L, Yang L, Xing F, Yang H, Qin L, Lan Y, Wu H, Zhang B, Shi H, Lu C, Huang F, Wu X, Wang Z. Gypenoside IX Suppresses p38 MAPK/Akt/NFκB Signaling Pathway Activation and Inflammatory Responses in Astrocytes Stimulated by Proinflammatory Mediators. Inflammation 2017;40:2137-50. [DOI: 10.1007/s10753-017-0654-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
10 Wang Z, Fu W, Huo M, He B, Liu Y, Tian L, Li W, Zhou Z, Wang B, Xia J, Chen Y, Wei J, Abliz Z. Spatial-resolved metabolomics reveals tissue-specific metabolic reprogramming in diabetic nephropathy by using mass spectrometry imaging. Acta Pharm Sin B 2021;11:3665-77. [PMID: 34900545 DOI: 10.1016/j.apsb.2021.05.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liu YL, Zhang QZ, Wang YR, Fu LN, Han JS, Zhang J, Wang BM. Astragaloside IV Improves High-Fat Diet-Induced Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Rats by Regulating Inflammatory Factors Level via TLR4/NF-κB Signaling Pathway. Front Pharmacol 2020;11:605064. [PMID: 33708118 DOI: 10.3389/fphar.2020.605064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jiang P, Ma D, Wang X, Wang Y, Bi Y, Yang J, Wang X, Li X. Astragaloside IV Prevents Obesity-Associated Hypertension by Improving Pro-Inflammatory Reaction and Leptin Resistance. Mol Cells 2018;41:244-55. [PMID: 29562733 DOI: 10.14348/molcells.2018.2156] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
13 Qiu Y, Yu H, Hu Y, Guo S, Lei X, Qin Y, Jian Y, Li B, Liu L, Peng C, Wang A, Wang W. Transcriptomic and metabonomic profiling reveal the anti-obesity effects of Chikusetsusaponin V, a compound extracted from Panax japonicus. J Pharm Pharmacol 2021;73:60-9. [PMID: 33791810 DOI: 10.1093/jpp/rgaa029] [Reference Citation Analysis]